BioHarvest Sciences Revises FY26 CDMO Revenue Guidance to $4M-$5M from $4M-$6M; VINIA D2C Revenue Guidance to $33M-$35M from $38M-$42M
BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business has been narrowed to $4 million-$5 million, from $4 million-$6 million previously, while revenue guidance for the VINIA
BioHarvest lowered its money forecasts for both parts of its business—the CDMO side stayed about the same, but VINIA is now expected to make less money than the company thought before. When a company lowers its forecast, it hints that things aren't going as well as hoped, so it's worth watching to see if they can catch back up.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.